ACRES Commercial Realty(US:ACR) Prnewswireยท2024-10-25 11:18Core Insights - Protalix BioTherapeutics is set to present data from a phase I clinical trial of PRX-115, a recombinant PEGylated uricase for uncontrolled gout, at the ACR Convergence 2024 [1] - The presentation will highlight the prolonged plasma urate-lowering effects after a single intravenous administration of PRX-115 [1] Company Overview - Protalix BioTherapeutics specializes in developing and commercializing recombinant therapeutic proteins using its proprietary ProCellEx plant cell-based expression system [2] - The company was the first to receive FDA approval for a protein produced through a plant cell-based expression system [2] - Protalix has licensed worldwide rights for taliglucerase alfa, its first product, to Pfizer, while retaining full rights in Brazil [2] Product Pipeline - Protalix's development pipeline includes PRX-115 for uncontrolled gout and PRX-119 for NETs-related diseases, among other proprietary recombinant therapeutic proteins [3]